ArticleAIDS care2022
Driving force of COVID-19 among people living with HIV in Wuhan, China.
Article in AIDS care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- The clinical outcomes of COVID-19 in HIV-positive patients: A systematic review of current evidence.Immunity, inflammation and disease · 2021Pooled it
- SARS-CoV-2 Antibodies in Response to COVID-19 Vaccination in Underserved Racial/Ethnic Minority People Living with HIV.Vaccines · 2025Article
- Investigating the relationship between the IL-17 rs2275913, IL-17 rs763780, and the IL-6 rs1800795 genotypes in HIV-positive patients with COVID-19.Molecular biology reports · 2025Article
- BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.Journal of medical virology · 2024Article
- Article
- The Impact of SIV-Induced Immunodeficiency on Clinical Manifestation, Immune Response, and Viral Dynamics in SARS-CoV-2 Coinfection.bioRxiv : the preprint server for biology · 2023Article
- Double Trouble Co-Infections: Understanding the Correlation Between COVID-19 and HIV Viruses.Cureus · 2023Review
- Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.BMC infectious diseases · 2023Article
- Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.Research square · 2022Article
- Enigma of the high prevalence of anti-SARS-CoV-2 antibodies in HIV-positive people with no symptoms of COVID-19 in Burkina Faso.Journal of public health in Africa · 2022Article
- Sexual health (excluding reproductive health, intimate partner violence and gender-based violence) and COVID-19: a scoping review.Sexually transmitted infections · 2021Article
- HIV and COVID-19: review of clinical course and outcomes.HIV research & clinical practice · 2021Article
- Clinical outcomes of COVID-19 amongst HIV patients: a systematic literature review.Epidemiology and health · 2021Article
- HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
Corrections and comments
- Update of
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAlthough people living with HIV (PLWH) were considered to be at increased risk of SARS-CoV-2 infection, the driving force among this group of individuals is still not clear.
methodsWe investigated 1,709 PLWH through a telephone interview and identified 11 COVID-19 patients in four districts of Wuhan, China. The demographic features and major clinical characteristics of these patients were retrieved from the information management systems for COVID-19 patients of the four districts' CDC. Statistical analysis was performed to find out the driving force of COVID-19 among PLWH.
resultsThe prevalence of COVID-19 in PLWH is 0.6% (95% CI: 0.2% - 1.0%), which is comparable to the overall population prevalence in Wuhan city (0.6%). Nine out of the 11 COVID-19 patients had relatively high CD4+ T lymphocyte count (>200/μl) and undetectable HIV viral load (<20 copies/ml), and ten of them were on antiretroviral therapy. Older PLWH with low CD4 + count, got HIV infected through homosexual activity, and had been diagnosed with HIV for a long time, were more likely to develop COVID-19.
conclusionsCOVID-19 related morbidity rates were comparable between PLWH and the general population. Older age with low CD4 count, an extended period of HIV diagnosis, and treatment-naivety were potential driving forces of COVID-19 prevalence among PLWH. Strategies for preventing SARS-CoV-2 infection among PLWH with weak immune responses are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.